Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Chan

Showing results (31-40 of 271) with videos related to

Pageof 28
Sort By:
Cancer Cell|October 11, 2024
The hallmarks of cancer immune evasionClaudia Galassi, Timothy A Chan, Ilio Vitale, et al.
Nature Cancer|June 28, 2022
The status of tumor mutational burden and immunotherapyValsamo Anagnostou, Alberto Bardelli, Timothy A Chan, et al.
Seminars in Radiation Oncology|May 9, 2020
Diverse Neoantigens and the Development of Cancer TherapiesRaghvendra M Srivastava, Tanaya A Purohit, Timothy A Chan
Cell Cycle (Georgetown, Tex.)|March 16, 2013
The FAT epidemic: a gene family frequently mutated across multiple human cancer typesLuc G T Morris, Deepa Ramaswami, Timothy A Chan
Human Molecular Genetics|October 8, 2020
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biologyRenzo G DiNatale, A Ari Hakimi, Timothy A Chan
Cell Cycle (Georgetown, Tex.)|April 8, 2010
The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin ESelvaraju Veeriah, Luc Morris, David Solit, et al.
Molecular & Cellular Oncology|June 17, 2016
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinomaMatthew Hellmann, Naiyer Rizvi, Jedd D Wolchok, et al.
Genes & Diseases|February 3, 2015
Unraveling the molecular genetics of head and neck cancer through genome-wide approachesNadeem Riaz, Luc G Morris, William Lee, et al.
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)Sanjay Anand, Timothy A Chan, Tayyaba Hasan, et al.
Trends in Immunology|May 13, 2018
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be DifferentChung-Han Lee, Roman Yelensky, Karin Jooss, et al.
Pageof 28

Showing results (31-40 of 271) with videos related to

Sort By:
Pageof 28
Cancer Cell|October 11, 2024
The hallmarks of cancer immune evasionClaudia Galassi, Timothy A Chan, Ilio Vitale, et al.
Nature Cancer|June 28, 2022
The status of tumor mutational burden and immunotherapyValsamo Anagnostou, Alberto Bardelli, Timothy A Chan, et al.
Seminars in Radiation Oncology|May 9, 2020
Diverse Neoantigens and the Development of Cancer TherapiesRaghvendra M Srivastava, Tanaya A Purohit, Timothy A Chan
Cell Cycle (Georgetown, Tex.)|March 16, 2013
The FAT epidemic: a gene family frequently mutated across multiple human cancer typesLuc G T Morris, Deepa Ramaswami, Timothy A Chan
Human Molecular Genetics|October 8, 2020
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biologyRenzo G DiNatale, A Ari Hakimi, Timothy A Chan
Cell Cycle (Georgetown, Tex.)|April 8, 2010
The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin ESelvaraju Veeriah, Luc Morris, David Solit, et al.
Molecular & Cellular Oncology|June 17, 2016
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinomaMatthew Hellmann, Naiyer Rizvi, Jedd D Wolchok, et al.
Genes & Diseases|February 3, 2015
Unraveling the molecular genetics of head and neck cancer through genome-wide approachesNadeem Riaz, Luc G Morris, William Lee, et al.
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)Sanjay Anand, Timothy A Chan, Tayyaba Hasan, et al.
Trends in Immunology|May 13, 2018
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be DifferentChung-Han Lee, Roman Yelensky, Karin Jooss, et al.
Pageof 28